CONTINUOUS LISURIDE EFFECTS ON CENTRAL DOPAMINERGIC MECHANISMS IN PARKINSONS-DISEASE

被引:76
|
作者
BARONTI, F [1 ]
MOURADIAN, MM [1 ]
DAVIS, TL [1 ]
GIUFFRA, M [1 ]
BRUGHITTA, G [1 ]
CONANT, KE [1 ]
CHASE, TN [1 ]
机构
[1] NINCDS, EXPTL THERAPEUT BRANCH,BLDG 10,ROOM 5C103, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA
关键词
D O I
10.1002/ana.410320611
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Effects of the long term, continuous administration of a dopamine agonist on motor response complications attending levodopa therapy were studied in 7 patients with advanced Parkinson's disease under controlled conditions. After a 3-month round-the-clock infusion of lisuride, the duration of antiparkinsonian action of levodopa increased by approximately 90%, and the therapeutic window for the acutely administered dopamine precursor widened by >300%. These benefits were more than three times greater than those produced by 9 days of continuous levodopa administration. In contrast to the effects on levodopa pharmacodynamics, the continuous infusion of lisuride did not prolong its action, suggesting a lisuride effect on presynaptic as well as postsynaptic dopaminergic mechanisms. These results lend further support to the view that continuous dopamine replacement ameliorates motor fluctuations and peak-dose dyskinesias that complicate standard levodopa regimens. Our findings further suggest that alterations at both presynaptic and postsynaptic levels contributing to these motor complications tend to normalize with the more physiological stimulation afforded by continuous replacement strategies, especially when given chronically.
引用
收藏
页码:776 / 781
页数:6
相关论文
共 50 条
  • [1] MODIFICATION OF CENTRAL DOPAMINERGIC MECHANISMS BY CONTINUOUS LEVODOPA THERAPY FOR ADVANCED PARKINSONS-DISEASE
    MOURADIAN, MM
    HEUSER, IJE
    BARONTI, F
    CHASE, TN
    ANNALS OF NEUROLOGY, 1990, 27 (01) : 18 - 23
  • [2] LISURIDE IN PARKINSONS-DISEASE
    LEIGUARDA, R
    MICHELI, F
    PARDAL, MF
    MEDICINA-BUENOS AIRES, 1985, 45 (01) : 29 - 34
  • [3] LISURIDE IN PARKINSONS-DISEASE
    LIEBERMAN, AN
    NEOPHYTIDES, A
    LEIBOWITZ, M
    KUPERSMITH, M
    WALKER, R
    ZASORIN, N
    KLEINBERG, D
    GOLDSTEIN, M
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1980, 27 (02) : 266 - 267
  • [4] LISURIDE IN PARKINSONS-DISEASE
    SCHACHTER, M
    BLACKSTOCK, J
    DICK, JPR
    GEORGE, RJD
    MARSDEN, CD
    PARKES, JD
    LANCET, 1979, 2 (8152): : 1129 - 1129
  • [5] CONTINUOUS DOPAMINERGIC STIMULATION IN PARKINSONS-DISEASE
    OBESO, JA
    LUQUIN, MR
    VAAMONDE, J
    GRANDAS, F
    LAGE, JMM
    CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 1987, 14 (03) : 488 - 492
  • [6] LISURIDE INFUSION FOR PARKINSONS-DISEASE
    OBESO, JA
    LUQUIN, MR
    LAGE, JMM
    ANNALS OF NEUROLOGY, 1983, 14 (01) : 134 - 134
  • [7] ORAL LISURIDE FOR PARKINSONS-DISEASE
    OBESO, JA
    LUQUIN, MR
    LAGE, JMM
    MEDICINA CLINICA, 1985, 85 (08): : 307 - 312
  • [8] PERGOLIDE AND LISURIDE FOR PARKINSONS-DISEASE
    LIEBERMAN, AN
    LEIBOWITZ, M
    NEOPHYTIDES, A
    KUPERSMITH, M
    MEHL, S
    KLEINBERG, D
    SERBY, M
    GOLDSTEIN, M
    LANCET, 1979, 2 (8152): : 1129 - 1130
  • [9] CARDIOVASCULAR EFFECTS OF LISURIDE CONTINUOUS INTRAVENOUS-INFUSION IN FLUCTUATING PARKINSONS-DISEASE
    CAPRIA, A
    ATTANASIO, A
    QUATRANA, M
    CANNATA, D
    FIORAVANTI, M
    STOCCHI, F
    RUGGIERI, S
    CLINICAL NEUROPHARMACOLOGY, 1989, 12 (04) : 331 - 338
  • [10] DISPOSITION OF ORAL LISURIDE IN PARKINSONS-DISEASE
    BURNS, RS
    GOPINATHAN, G
    HUMPEL, M
    DOROW, R
    CALNE, DB
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1984, 35 (04) : 548 - 556